1.. Background {#S0001}
==============

Post-Traumatic Stress Disorder (PTSD) is a common and severe mental disorder with profound public health impact due to its high prevalence, chronicity, associated functional impairment and frequent comorbidities (Kessler, [2000](#CIT0039); Kessler, Sonnega, Bromet, Hughes, & Nelson, [1995](#CIT0040); Shalev, Liberzon, & Marmar, [2017](#CIT0066)). Early PTSD symptoms, frequently observed shortly after trauma exposure, subside in most of those initially expressing them, persisting in about 30% of those who meet PTSD diagnostic criterial 1 month after trauma (Davidson, Stein, Shalev, & Yehuda, [2004](#CIT0015); Freedman, Brandes, Peri, & Shalev, [1999a](#CIT0024); Koren, Arnon, & Klein, [2001](#CIT0045); O'Donnell, Creamer, Bryant, Schnyder, & Shalev, [2003](#CIT0051); Peleg & Shalev, [2006](#CIT0052); Perkonigg et al., [2005](#CIT0053); Shalev, [1996](#CIT0067); Shalev, Peri, Canetti, & Schreiber, [1996](#CIT0073); Yehuda, McFarlane, & Shalev, [1998a](#CIT0083)). Additionally, some initially asymptomatic survivors develop delayed-onset PTSD (Shalev et al., [2019](#CIT0072)). The occurrence of chronic PTSD in a limited subset of trauma-exposed survivors, and the tenacity of the chronic condition, suggest a long-lasting neurobehavioral modification (Pitman et al., [2012](#CIT0056)). Longitudinal studies, therefore, classify early PTSD symptom into trajectories of non-remission, rapid remission, and delayed (often incomplete) remission (Marmar, Weiss, & Schlenger et al., [1994](#CIT0049); Mayou, Tyndel, & Bryant, [1997](#CIT0050); Stein, Walker, Hazen, & Forde, [1997](#CIT0078); Yehuda, McFarlane, & Shalev, [1998b](#CIT0084)).

Symptom trajectories provide an observable dimension of PTSD development, or remission. To better understand the underlying neurobiology of PTSD pathogenesis and resilience, these trajectories must be linked with co-occurring developments in objectively measured cognitive functioning, brain structure, and brain function. Such studies must be large enough to allow an exploration of the resulting multimodal matrix. To date, however, large-scale longitudinal studies combining cognitive and neuroimaging with PTSD symptom trajectories are missing.

1.1.. Cognitive Functioning {#S0001-S2001}
---------------------------

Several cognitive deficits have been previously linked with PTSD (Scott et al., [2015](#CIT0064)) including working memory, information processing speed, verbal learning, short-term and declarative memory (Johnsen & Asbjørnsen, [2008](#CIT0036); Samuelson, [2011](#CIT0062)), attention, and executive functioning (Aupperle, Melrose, Stein, & Paulus, [2012](#CIT0004); Polak, Witteveen, Reitsma, & Olff, [2012](#CIT0057)). PTSD has additionally been associated with poor response inhibition, attentional switching and flexibility (Casada & Roache, [2005](#CIT0014); Hart et al., [2017](#CIT0033); Koenen et al., [2001](#CIT0044); Leskin & White, [2007](#CIT0047); Vasterling, Brailey, Constans, & Sutker, [1998](#CIT0080)), and these features were hypothetically linked with PTSD patients' difficulties to disengage from attending salient stimuli (Pineles, Shipherd, Mostoufi, Abramovitz, & Yovel, [2009](#CIT0055)).

1.2.. Brain Structure {#S0001-S2002}
---------------------

Several structural brain abnormalities have been associated with chronic PTSD (Bonne et al., [2001](#CIT0011); Gilbertson et al., [2002](#CIT0030)), including reduced volume of the hippocampus, medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC), as well as thinner dorsolateral prefrontal cortex (dlPFC) (Bremner, Elzinga, Schmahl, & Vermetten, [2007](#CIT0012); Ferrari, Busatto, McGuire, & Crippa, [2008](#CIT0020); Gilbertson et al., [2002](#CIT0030); Kasai et al., [2008](#CIT0038)). Alterations in white matter have also been implicated in top-down regulation deficits in PTSD patients (Abe et al., [2006](#CIT0001); Admon et al., [2013](#CIT0002); Kim et al., [2007](#CIT0041); Schuff et al., [2011](#CIT0063)). Diffusion tensor imaging (DTI) studies of PTSD have documented changes in fractional anisotropy in the posterior cingulum bundles, connecting cingulate and entorhinal cortices (Fani et al., [2012](#CIT0019); Kim et al., [2007](#CIT0041); Zhang et al., [2010](#CIT0085)), as well as decreased white matter integrity in the uncinate fasciculus (Ayling, Aghajani, Fouche, & van der Wee, [2012](#CIT0005); Phan et al., [2009](#CIT0054)).

1.3.. Brain Function {#S0001-S2003}
--------------------

Functional neural systems associated with PTSD include fear learning, threat detection, executive function and emotion regulation, and contextual processing (Shalev et al., [2017](#CIT0066)). Altered activity in the neural circuits mediating these systems (i.e., the amygdala, ventromedial prefrontal cortex (vmPFC), dorsal anterior cingulate cortex (dACC), hippocampus, and insula) have been found in PTSD (reviewed in (Liberzon & Sripada, [2007](#CIT0048); Pitman et al., [2012](#CIT0056); Shin, Rauch, & Pitman, [2006](#CIT0074))). Finally, resting-state connectivity studies in PTSD showed reduced coupling within the default mode network (DMN), greater coupling within the salience network (SN), and decreased segregation of the DMN and SN (Koch et al., [2016](#CIT0043); Sripada et al., [2012](#CIT0076)). These connectivity patterns suggest possible biomarkers for PTSD and its dissociative subtype.

Studies outlined above have lead to several mechanistic hypotheses of PTSD pathogenesis (Pitman et al., [2012](#CIT0056); Shalev et al., [2017](#CIT0066)). Testing these pathogenic hypotheses, however, requires longitudinal studies, optimally carried out during the early aftermath of traumatic events, simultaneously exploring multimodal dimensions of the response to trauma (e.g., symptoms, cognitive functions, brain structure and functioning). Such studies are challenging: their design must accommodate subjects' burden and expected attrition; their size should allow statistical inference; to truly assess PTSD pathogenesis, they should remain with a large enough number of PTSD patients at endpoint; Finally, their contents and timing should address the critical stages in PTSD longitudinal development. Given such constraints, designing multimodal studies of PTSD development requires methodological choices and trade-offs, as well as a clear delineation of theoretically pertinent, feasible and attainable goals.

Exemplifying such constraints and choices, we present here the design of a multimodal longitudinal study of neurobehavioral moderators of PTSD trajectories, that concurrently documents PTSD symptom trajectories, cognitive functioning, brain structure and theoretically compelling brain functions.

The study's stated aims and hypothesis are the following: (1) to *document PTSD symptoms trajectories* during the year that follows trauma exposure, and evaluate the contribution of putative covariates (e.g., co-occurring depression and anxiety; trauma type, age, gender) to these trajectories. Following previous studies (Galatzer-Levy et al., [2013](#CIT0028)) we expected to uncover distinct longitudinal trajectories hypothetically encompassing rapid remission, slow or delayed remission or non-remission. (2) To identify *cognitive mechanisms* that predict or accompany PTSD symptom trajectories, using a comprehensive battery of cognitive functioning described below. (3) To identify *neural mechanisms* that predict or accompany PTSD symptom trajectories, using functional MRI (fMRI) of resting-state functional connectivity and specific cognitive-emotional probes described below. (4) To identify *structural brain alterations* associated with PTSD symptom trajectories, using high-resolution structural MRI and Diffusion Kurtosis Imaging (DKI). We hypothesized that initial structural abnormalities of grey matter (e.g. smaller hippocampus) and white matter (e.g. reduced white matter integrity of the uncinate fasciculus) would be associated with the non-remission symptom trajectory. (5) To explore *the multi-level integration* of cognitive and neural variables associated with PTSD symptom trajectories (exploratory aim).

Following previous success in conducting longitudinal studies of PTSD (Marmar et al., [1994](#CIT0049); Mayou et al., [1997](#CIT0050); Stein et al., [1997](#CIT0078); Yehuda et al., [1998b](#CIT0084)), we opted to study adult survivors of traumatic events admitted to a general hospital ER following trauma exposure, and used previous work (Bonne et al., [2001](#CIT0011); Shalev et al., [2012a](#CIT0068); Shalev, Ankri, Peleg, Israeli-Shalev, & Freedman, [2011](#CIT0070)) to infer the expected sample size, attrition and PTSD prevalence at endpoint. Aiming to capture at least 1 year of PTSD early development, and attempting to avoid the 12 months 'anniversary reaction', we followed the participants for a period of 14 months.

2.. Methods {#S0002}
===========

2.1.. Study design {#S0002-S2001}
------------------

The following study is designed as an observational, prospective panel study of consecutive trauma survivors admitted to a general hospital emergency room (ER) following traumatic incidents. To reveal and document the neurobehavioral moderators of PTSD symptom trajectories, this work will repeatedly and simultaneously evaluate trauma survivors' clinical symptoms, cognitive performance, brain structure and neural functioning at 1, 6, and 14 months following trauma exposure (Time Point 1, Time Point 2 and Time Point 3; TP1, TP2, and TP3, respectively).

2.2.. Participant eligibility (inclusion and exclusion criteria) {#S0002-S2002}
----------------------------------------------------------------

Participants will constitute adult survivors of traumatic events, admitted to Tel Aviv Sourasky Medical Centre's ER. Individuals will be considered for telephone screening interview if they meet the following inclusion criteria: (i) Age 18--65 years (ii) Able to read and comprehend Hebrew; (iii) Arrived in the ER after experiencing one of the following traumatic events: motor-vehicle accident (MVA), bicycle accident, work accident, terror attack, hostilities, physical assault, electric shock, fire, robbery, drowning or large-scale disaster.

Eligible individuals will not be included in the study if they sustained severe head injury or were a coma upon ER arrival; have known medical condition that interfere with their ability to give informed consent, cooperate with screening and/or treatment; suspected or diagnosed with chronic PTSD; have a lifetime history of psychotic illness; have current substance abuse disorder; express suicidal ideations or have other medical or psychological conditions that constitute treatment priority upon potential enrolment. Individuals who are not eligible for an MRI scan will be similarly excluded (e.g. those with pacemakers, implants that are not MRI-compatible, permanent makeup or large tattoos, and those known to suffer from claustrophobia). Due to the Ministry of Defence regulations, active service members of the Israel Defence Force (IDF) will not be included in this study.

2.3.. Clinical instruments {#S0002-S2003}
--------------------------

*Clinician-Administered PTSD Scale (CAPS) IV and 5* (Blake et al., [1995](#CIT0009); Weathers, Bovin, & Lee et al., [2018](#CIT0081)). Structured clinical interview evaluating DSM-IV and DSM-5 PTSD symptom criteria on dimensions of frequency, intensity, and severity. An instrument combining both CAPS-IV and CAPS-5 will be used in order to keep continuity, after the DSM criteria changed. The CAPS contain explicit, behaviourally anchored probes for each PTSD symptom criteria and rating scale descriptors to enhance reliability. It yields both categorical notation of each symptom (present/absent) and continuous symptom severity score. The CAPS total score will be obtained by summing all individual items' scores, serving as the main outcome measure of this study. CAPS-5 includes items assessing the dissociative subtype of PTSD (depersonalization and derealization severity). The Hebrew version which will be used in this work was cross-translated and compared with the original English instruments. CAPS-5 demonstrates high internal consistency (α = 0.88) and high test--retest reliability (ICC = 0.78), as well as good convergent validity with CAPS-IV (r = 0.83) and PTSD Checklist for DSM--5 (r = 0.66) (Weathers et al., [2018](#CIT0081)).

*Structured clinical interview for DSM-IV (SCID-IV)* (First, [1995](#CIT0022)). Structured clinical interview evaluating current and lifetime (pre-event) Axis I mental disorders. The official Hebrew version of SCID has been used extensively in the previous PTSD research (Hirschfeld et al., [2000](#CIT0034); Rohde, Lewinsohn, & Seeley, [1997](#CIT0061)).

*PTSD Checklist for DSM-IV (PCL)* (Weathers, Litz, Herman, Huska, & Keane, [1993](#CIT0082)). A 17-item self-report questionnaire, corresponding to the DSM-IV symptom criteria for PTSD. PCL measures the distress caused from each PTSD symptom over the past month, using a 5‐point scale ranging from 1 = not at all to 5 = extremely. PCL item scores will be summed to yield a secondary continuous measure of PTSD symptom severity, in addition to CAPS total scores. It was shown to have high test--retest reliability over a three-day period (r = 0.96) and very high internal consistency (α = 0.97) as well as a high correlation with CAPS (Blanchard, [1996](#CIT0010)). This measure was cross-translated to Hebrew and used in previous studies (Ben-Zion et al., [2018](#CIT0008); Fine, Achituv, Etkin, Merin, & Shalev, [2018](#CIT0021)).

*Beck Depression Inventory (BDI-II)* (Beck, Steer, & Brown, [1996](#CIT0007)). 21-item self-report questionnaire, which will assess the severity of current depressive symptoms. The BDI was shown to have high internal consistency (α = 0.97) and high test--retest reliability (r = 0.93). It's Hebrew version was used in prospective studies of PTSD, where it was found to be a good predictor of chronic PTSD at 1-week and 1-month after trauma (Freedman et al., [1999a](#CIT0024)).

*Beck Anxiety Inventory (BAI)* (Beck, Epstein, Brown, & Steer, [1988](#CIT0006)). 21-item self-report questionnaire measuring concurrent anxiety symptoms. The BAI was shown to have high internal consistency (α = 0.88) and good test--retest reliability over 1-week (r = 0.75). Previously, BAI discriminated anxious diagnostic groups (panic disorder, generalized anxiety disorder, etc.) from non-anxious diagnostic groups (major depression, dysthymic disorder, etc.), and was moderately correlated with other anxiety rating scales (Fydrich, Dowdall, & Chambless, [1992](#CIT0027)).

*Participants' Clinical Global Impression scale (CGI-P)* (Guy, [1976](#CIT0031)). Self-report, easily understood practical measurement tool (Busner & Targum, [2007](#CIT0013)), which will be used to evaluate patients' subjective impression, on a scale between 1 ('normal feeling') to 7 ('the worst feeling there is').

2.4.. Cognitive functioning measures {#S0002-S2004}
------------------------------------

Cognitive tests will be administered via WebNeuro, a validated world-wide-web-based comprehensive battery of cognitive functioning (Silverstein et al., [2007](#CIT0075)). To standardize testing conditions, all tests will be taken in the Hebrew language at our laboratory, rather than in participants' homes. Performance in the different tasks included in WebNeuro battery will be calculated using an automated software program, standardizing performance for age and years of education. For each participant, standardized z-scores will be derived from all the relevant outcome measured, at each of the following 11 cognitive functions: **motor coordination, processing speed, sustained attention, controlled attention, cognitive flexibility, response inhibition, working memory, recall memory, executive function, emotion identification, and emotional bias** *(see the specific tests, measured constructs, instructions and outcome measures in* [*Table 1*](#T0001)).10.1080/20008198.2019.1683941-T0001Table 1.Cognitive measures. Specific cognitive tests, measured constructs, instructions for participants, and outcome measures of the cognitive measures which will be used in the study.TestsMeasured constructInstructionsOutcome measures1. Tapping testMotor coordinationParticipants will be required to tap the space bar with their index finger, as fast as possible for 30 seconds.Number of Taps, Variability of Pauses Between Taps.2. Reaction time testProcessing speedParticipants will be presented with two black circles on the screen. When the left circle will turn green, they will be instructed to press the left arrow button as fast as possible with their left hand. When the right circle will turn green, they will be instructed to press the right arrow button as fast as possible with their right hand.Reaction Time.3. Verbal memory test\
(Immediate)Recall memoryA list of twenty words will be presented one by one. Individuals will then be presented with twenty sets of three response words (one word from the list and two new words). For each set of three words, they will be instructed to select the one word that was previously presented.Total Accuracy and Reaction Times for Immediate Recall Responses.4. Verbal memory test\
(Delayed)Recall memoryTen minutes later, after several other tasks, individuals will again be presented with twenty sets of three response words (one word from the list and two new words). For each three words, they will be instructed to select the one word that was previously presented.Total Accuracy and Reaction Times for Delayed Recall Responses.5. Emotion identification testEmotion identificationThis task will include a series of faces that will be presented on the screen, each displaying one of six emotional expressions (fear, anger, disgust, sadness, happiness, or neutral). On each trial, participants will have to select the emotion label that best matches each face from the six response buttons displayed beneath the face, as quickly and as accurate as possible.Accuracy and Reaction Time will be measured for each one of the six emotional faces types separately.6. Emotional bias testEmotional biasTen minutes later, after several other tasks, participants will be presented with different sets of two emotional faces, one which will be identical to a face presented in the previous task (Emotion Identification task), and a second new face. Individuals will be instructed to use the mouse to determine which of the two faces was presented in the previous task.Accuracy and Reaction Time will be measured for each one of the six emotional faces types separately.7. Digit span testWorking memoryParticipants will be presented with a series of digits on the screen (one by one) and will then be instructed to type them in the exact order in which they were displayed.Maximum Recall Span, and Correct Trials.8. Stroop task (Stroop, [1935](#CIT0079))Controlled attentionParticipants will be presented with colour names printed in either "matched" (e.g. the word RED printed in red ink) or "mismatched" colours (e.g. the word RED printed in green ink). In the first part, they will be asked to indicate the meaning of the word, while disregarding the ink colour. In the second part, they will have to do the opposite, meaning to indicate the ink colour, while disregarding the meaning of the word.Reaction Time and Accuracy for each Type of Condition (Congruent/Incongruent), Number of Congruent and Incongruent Trials Completed (in 20 seconds).9. Trail making test (Reitan, [1958](#CIT0059))Cognitive flexibilityParticipants will be asked to connect 25 circles according to the correct order, as fast as possible. In the first part, they will be presented with 25 numbers and will have to connect them by order (from 1 to 25). In the second part, they will be presented with a combination of 13 numbers (1--13) and 12 letters (A-L) and will be instructed to switch back and forth between numbers and letters in an ascending pattern (e.g. 1-A-2-B, etc.). Note: to match mother tongue we will use Hebrew letters.Response Accuracy, Completion Time and Connection Time.10. Inhibition test (Go/No-Go Task)Response inhibitionParticipants will be instructed to press the space bar when the word appears in green and to inhibit their response when the word appears in red.Accuracy, Errors of Commission and Omission, Reaction Time and its Variability.11. Maze TaskExecutive functionParticipants will be presented with an 8 × 8 matrix of red circles. They will be required to discover and remember a fixed, hidden path through the grid, from a yellow starting dot on the bottom row to a blue finishing dot on the top row while receiving feedback during the task. A total of 24 correct moves is required to navigate to the finishing dot. The task will end when the full path is completed without errors twice in a row, or when the maximum task duration of 5 minutes is reached.Trials completed,\
Completion time,\
Path learning time,\
Total errors and Overrun errors.12. Continuous performance testSustained attentionParticipants will be presented with a serious of letters and will be instructed to respond when they detect the same letter appears twice in a row. The task includes 63 stimuli, with 12 'response' trials where the same letter is repeated twice in a row. Task duration is approximately 3 minutes.Accuracy,\
False Miss Errors,\
False Alarm Errors, Reaction Time and its Variability.13. Emotional stroop testEmotional biasParticipants will be presented with a facial expression of 'happiness' or 'fear', together with the word 'happy' or 'fear' placed on the face. The participant will be instructed to indicate the facial expression, while ignoring the word placed on it. Participates are guided to make their response as accurate and quickly as possible.Accuracy and Reaction Time for Congruent and Incongruent Trials,\
Reaction Time for Interference.

2.5.. Imaging data acquisition {#S0002-S2005}
------------------------------

Structural and functional scans will be performed in a 3.0 Tesla Siemens MRI system (MAGNETOM Prisma, Germany), using a twenty-channel head coil, located at the Sagol Brain Institute at Tel-Aviv Sourasky Medical Centre. To allow high-resolution whole-brain structural images, both T1-weighted magnetization prepared rapid gradient echo (MPRAGE) (TR/TE = 2400/2.29 ms, flip angle = 8°, voxel size 0.7 × 0.7 × 0.7 mm, FOV = 224 × 224 mm) and Diffusion Kurtosis Imaging (DKI) sequences (30 diffusion directions, b = 0/1000/2000 s/mm2, TR/TE = 8200/69.0 ms, voxel size 2.2 × 2.2 × 2.2 mm, FOV = 220 × 220 mm) will be acquired. Functional whole-brain scans will be performed in an interleaved order, using a T2\*-weighted gradient echo-planar imaging pulse sequence (TR/TE = 2000/28 ms, flip angle = 90°, voxel size 2.2 × 2.2 × 2.2 mm, FOV = 220 × 220 mm, slice thickness = 3 mm, 36 slices per volume).

2.6.. Imaging data analysis {#S0002-S2006}
---------------------------

Imaging data will be analyzed using validated softwares, including FMRIB Software Library (FSL) (Jenkinson, Beckmann, Behrens, Woolrich, & Smith, [2012](#CIT0035)), Statistical Parametric Mapping (SPM) (Friston et al., [1994](#CIT0026)), and FreeSurfer (Fischl, [2012](#CIT0023)).

2.7.. fMRI tasks {#S0002-S2007}
----------------

### 2.7.1.. Resting-state scan {#S0002-S2007-S3001}

A functional resting-state scan (duration = 10 min, TR = 2000 ms, TE = 28 ms, 3 × 3 × 3mm voxel size), in which participants will be instructed to keep their eyes open and fixed on a fixation cross, will be used to examine functional activity and connectivity of different neural regions (e.g. amygdala, hippocampus, prefrontal cortex) and networks at rest (e.g. salience network, default-mode network).

### 2.7.2.. Emotional reactivity task {#S0002-S2007-S3002}

Subjects will perform the emotional faces matching task (Hariri, Bookheimer, & Mazziotta, [2003](#CIT0032)), in which they will be instructed to select the shape (located at the bottom right or bottom left of the screen) that matches the target face/shape (located at the top of the screen), as accurate and as quickly as possible. The task will include four blocks of shapes, and four blocks of emotional faces (angry, fearful, surprised and neutral faces). The order of the emotional faces blocks will be counterbalanced between subjects, as well as within-subjects across different time-points, using four different versions for this task. We will use this task mainly to evaluate individuals' emotional reactivity and regulation.

### 2.7.3.. Risk and reward sensitivity task {#S0002-S2007-S3003}

Participants will play an interactive-modified domino game (Admon et al., [2013](#CIT0003)), in which they will be forced to take risks in order to win (Kahn et al., [2002](#CIT0037)). This paradigm involves four intervals: decision making (goal-conflict behaviour), execution (risky vs. safe choice), anticipation (emotional regulation), and outcome (punishment, non-punishment, reward, non-reward). We will use this task mainly to evaluate sensitivity to signals of risk and reward, emotional regulation motivation processing.

### 2.7.4.. Emotion regulation task {#S0002-S2007-S3004}

Attention- and appraisal-based emotion regulation will be probed using the Shifted-Attention Emotion Appraisal Task (SEAT) (Duval, Joshi, Russman Block, Abelson, & Liberzon, [2018](#CIT0018); Klumpp et al., [2011](#CIT0042); Sripada et al., [2013](#CIT0077)). Stimuli in this task include composite pictures of superimposed faces (foreground) and buildings (background), as well as 20 pictures of faces or buildings only. The face pictures depict neutral, angry, or fearful expressions, and the building pictures depict indoor or outdoor scenes. In three different conditions, participants will be asked to respond to three different questions: (1) Gender (Male/Female): whether the face in the foreground is male or female; (2) Inside/Outside: whether the scene in the background is indoors or outdoors; and (3) Like/Dislike: whether the face in the foreground is liked or disliked. This task will probe multiple components of emotion regulation, including (1) implicit emotional processing, (2) attentional modulation of emotion, and (3) modulation of emotion by appraisal.

2.8.. Procedure {#S0002-S2008}
---------------

### 2.8.1.. Source of participants {#S0002-S2008-S3001}

Potential trauma survivors will be identified via Tel Aviv Sourasky Medical Centre's ER computerized medical records, following potential traumatic events.

### 2.8.2.. Screening and initial telephone assessment {#S0002-S2008-S3002}

Within 10--14 days after trauma exposure, and after being discharged from the hospital, identified individuals will be contacted by telephone for an initial screening. After explaining the purpose of the call and obtaining verbal consent, a modified dichotomous version of the PCL will be administered. Potential participants which will report symptoms that will meet DSM-IV or DSM-5 PTSD diagnostic criteria (except for the 1-month duration), and will not meet any of the exclusion criteria, will receive further verbal information about the research and will be invited for a face-to-face interview. The telephone screening will be conducted by B.A. and M.A. level students which will receive specialized training and will be certified to use these specific assessment tools.

### 2.8.3.. Clinical assessment {#S0002-S2008-S3003}

After signing an informed consent, the participants will be evaluated by CAPS and SCID (described above), will complete four self-report questionnaires (PCL, BDI-II, BAI, and CGI) and a battery of cognitive tests (WebNeuro). Participants who will meet CAPS-based DSM-IV or DSM-5 Acute PTSD diagnostic criteria, and will not meet any of the exclusion criteria, will be invited for a structural and functional MRI scan. Although the study will preferentially enrol survivors who meet PTSD diagnosis (and are thus at risk of chronic PTSD), we will also enrol individuals with sub-threshold PTSD.

It is important to note that the selection of individuals with initial high PTSD symptom severity was intended to generate a large enough sample of PTSD individuals at the end of the study. This is based on previous literature showing that survivors with early PTSD symptoms are at high risk of developing chronic PTSD, and that an absence of early symptoms reliably predicts a good prognosis (Freedman, Brandes, Peri, & Shalev, [1999b](#CIT0025); Shalev et al., [2012b](#CIT0069); Shalev, Freedman, Peri, & Brandes, [1997](#CIT0065); Shalev et al., [2019](#CIT0072)).

The first clinical meeting will take approximately 3 h, including clinical interview, self-report questionnaires and cognitive assessment (Meeting \#1). The second meeting will take approximately 2 h, including high-resolution structural and functional MRI scan (Meeting \#2). Both meetings will take place at our laboratory, within 1 month after trauma (Time Point 1, TP1). Identical follow-up meetings (similar to both Meeting \#1 and Meeting \#2) will be conducted at 6 and 14 months after trauma (Time Point 2 and Time Point 3, TP2 and TP3 accordingly). Participants will receive financial remuneration at the end of each meeting of each time-point (TP1, TP2 and TP3), according to the ethics committee regulations and approval.

2.9.. Sample size {#S0002-S2009}
-----------------

We estimated sample size based on previous ER prospective studies of recent survivors, including attrition in an MRI study (Bonne et al., [2001](#CIT0011)) and in a prevention study using similar recruitment and follow-up approach (Shalev et al., [2012b](#CIT0069), [2011](#CIT0070)). The number of subjects was calculated with the goal of reaching n = 42 individuals diagnosed with PTSD at 14 months (TP3), considering expected subject loss (including MRI-related dropouts), as well as estimated spontaneous recovery (see [Figure 1](#F0001)).10.1080/20008198.2019.1683941-F0001Figure 1.Study flowchart.

We intend to screen 2800 adult civilians admitted to the hospital's ER, to confirm the occurrence of a psychologically traumatic event, and identify and assess those expressing initial PTSD symptoms via telephone-based structured interviews within 10--14 days of ER admission (target n = 1200). We then plan to conduct face-to-face clinical interviews of 720 consenting participants within 30 days of ER admission (TP1), and enrol 240 consenting participants, performing the first MRI scans within 30 days of ER admission (TP1). Assuming 36% loss of subjects to MRI sessions, we will perform 180 MRI sessions at 6 months (TP2) and 153 at 14 months after trauma (TP3). Clinical interviews will proceed regardless of MRI participation, with expected 240 participants at 6 and 14 months after trauma (TP2 and TP3). Structured telephone interviews could replace clinical assessments in participants who might decline repeated clinical contacts. Taken into account spontaneous recovery, we expect n = 42 individuals with PTSD diagnosed at 14-months post-trauma (TP3), and the remaining n = 111 individuals with partial or no PTSD diagnosis (see [Figure 1](#F0001)).

2.10.. Statistical analysis {#S0002-S2010}
---------------------------

PTSD latent symptom trajectories will be calculated using Latent Group Mixture Modelling (LGMM) analytic approach. Cognitive domains, brain structure and function will be examined in relation to these symptom trajectories. A 'trajectory' group x time factorial analysis will be conducted to identify progressive changes in cognitive domains, brain structure and function, associated with the different trajectories. Our statistical analyses will include key-covariates such as PTSD comorbidities, trauma type, age and gender. Corrections for multiple testing will be addressed through false discovery rate (FDR) corrected p values.

3.. Conclusions {#S0003}
===============

This work presents a study design aiming to uncover neurobehavioral moderators of PTSD trajectories in recent trauma survivors at substantial risk for PTSD (i.e., individuals with high initial symptoms). The study protocol is outlined in order to offer researchers an opportunity to evaluate and implement the methodology carefully chosen for this research.

Longitudinal studies of the early development of post-traumatic psychopathology present significant technical and conceptual challenges (Fine et al., [2018](#CIT0021); Qi et al., [2018](#CIT0058); Shalev et al., [2011](#CIT0070)). Technical challenges include reaching out to, enrolling, evaluating and retaining participants in sufficient numbers and proportions to ensure power and reduce retention bias. It is also critical to choose adequate tools and probes which are pertinent to constructs of interest (i.e. disease trajectories, hypothetical pathogenic and pathophysiological mechanisms). Conceptually, and more importantly, studies' design and implementation must address sample representativeness, for purposes of generalizability and specification of the population sample.

This study is designed to address some of these challenges in the following matter. First and foremost, PTSD definition of post-traumatic psychopathology is a symptom configuration that varies upon DSM taxonomic classification. Although DSM-based PTSD criteria is the most extensively studied outcome of trauma exposure, the specific diagnostic criteria has been recently modified and is an object of ongoing discussion (Do, [2011](#CIT0017); Galatzer-Levy & Bryant, [2013](#CIT0029); Zoellner, Bedard-Gilligan, Jun, Marks, & Garcia, [2013](#CIT0086)). In order not to limit ourselves to one of the frequently changing definitions of PTSD, we will use an assessment instrument that combines the two most recent symptom templates (i.e. DSM-IV and DSM-5), as well as self-report measures including indicators of anxiety and depression, that will portray a full picture of diagnostic features that are associated to PTSD manifestation.

Second, determining the timing of assessments is crucial for deriving adequate conclusions (Shalev et al., [2011](#CIT0070)). Overall, this study will include four repeated measurements of clinical data in the first year after trauma, chosen to assess the development and persistence of PTSD during this year. This design will allow us to capture: (1) early emerging symptoms (at 10--14 days post-trauma); (2) the key time point to discriminate early PTSD symptoms from fully developed syndrome (at 1-month post-trauma) (Shalev et al., [2012b](#CIT0069)); (3) an intermediary point enabling us to capture the evolving pathogenesis and pathophysiological PTSD mechanisms (at 6 months post-trauma); (4) endpoint hallmark encompassing the probability of sustaining chronic PTSD (at 14 months post-trauma), by which over 90% of recovery from PTSD is expected (Kessler et al., [1995](#CIT0040); Shalev & Freedman, [2005](#CIT0071)). This endpoint was chosen to avoid the 1-year 'anniversary' exacerbation of traumatic memories and symptoms.

Third, minimizing the subject loss in longitudinal designs is a well-known, often unresolved challenge. Here we address this a-priori by choosing to conduct the study on the Israeli population, known for its relatively high compliance, as well as situating it in a large metropolitan, easily accessible to the large population. Furthermore, the study will enable considerable flexibility and special attention to each one of the participants' needs (e.g. arranging transportation, flexible times of assessments, modified MRI scans, etc.). In addition, special emphasis will be given on strengthening the rapport between the participants and the research team (e.g. frequent contact with participants after and between different time points, issuing a study newsletter, etc.).

Nevertheless, this study design has also several limitations. First, as in most PTSD studies, there is a lack of baseline measurement before trauma exposure. However, as structural brain changes typically take time to occur, it is likely to assume that structural abnormalities detect pre-disposition factors, rather than consequence of trauma exposure. Second, for ethical reasons, we will not prevent individuals from seeking and participating in different treatments (pharmacological or psychotherapy), even though it might affect the natural course of the pathophysiologic development. Nevertheless, information regarding treatment timing and type will be recorded, thus could be accounted for. In addition, dissociation was not evaluated in depth (i.e. CAPS de-realization and de-personalization items were the only dissociative features captured in this work). Although dissociative PTSD subtype was previously associated with altered neural mechanisms (Lanius et al., [2010](#CIT0046)), it was most common among PTSD stemming from childhood trauma (De Bellis, Woolley, & Hooper, [2013](#CIT0016); Rivera-Vélez, González-Viruet, Martínez-Taboas, & Pérez-Mojica, [2014](#CIT0060)).

Despite many breakthroughs in technology, medicine and neuroscience research, there are still many gaps in our understanding and ability to predict PTSD trajectories. Being among one of the only mental disorders that has a defined onset, PTSD is an excellent target for secondary prevention and for mapping pathogenic processes. This study proposes the next necessary step, a large functional and structural brain imaging study of the evolving psychopathological consequences of traumatic events, enhancing our understanding of the nature of traumatic stress responses and its aftermath. Linking PTSD symptom trajectories with pertinent brain alterations (present initially, or developing simultaneously) and cognitive functioning, will contribute to classification and prediction of PTSD. While non-remitting symptom trajectory will inform the pathogenesis of chronic PTSD, a rapid remission trajectory may inform the science of resilience and recovery from trauma. Finally, our integrative, mechanism-oriented exploratory approach, may lead to improved early treatment and prevention of PTSD, thus improving the life of trauma survivors and increasing the cost-effectiveness of personalized intervention.
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